Inactive Instrument

Other languages Interpace Biosciences, Inc. Other OTC

Equities

IDXG

US46062X3035

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07
Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board?s Regulatory Compliance Committee	12-12
Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director	11-16
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08
Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
Interpace Biosciences, Inc. Expects to Stop Offering Pancragen Test Due to CMS Decision to End Reimbursement as of July 17, 2023	05/06/23
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Principal Financial Officer	25/04/23
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	27/03/23
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	27/03/23
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/03/23
Interpace Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	26/03/23
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
Interpace Biosciences, Inc. Announces New Clinical Validation Data	01/09/22
Flagship Biosciences, Inc. acquired Interpace Pharma Solutions from Interpace Biosciences, Inc..	30/08/22
Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Posts Q2 Revenue $9.4M	15/08/22
Interpace Biosciences, Inc. Announces New Clinical Validation Data for Thyroid Cancer Test Platform Published Online Within Thyroid®, the Leading Peer-Reviewed Journal for Original Research on Thyroid Cancer	15/08/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Interpace Biosciences, Inc. Other OTC

Equities

IDXG

US46062X3035

Other languages

Filters